• Rotigotine Hydrochloride: Dopamine D2/D3 Agonist in PD Resea

  2026-07-03

  Rotigotine hydrochloride enables precise modulation of dopaminergic pathways in Parkinson’s disease models, offering both neuroprotection and symptomatic improvement. This article details practical protocols, troubleshooting strategies, and translational advances—empowering researchers to maximize reliability and reproducibility in preclinical studies.

• Luminescent ATP Cell Viability Assay Kit I: Workflow & Insig

  2026-07-03

  The Luminescent ATP Cell Viability Assay Kit I streamlines and accelerates high-sensitivity cell viability measurement using luciferase luminescence detection. Its rapid, no-lysis workflow and ultra-low cell detection threshold empower robust cytotoxicity, proliferation, and metabolism studies—outperforming traditional colorimetric assays for modern research needs.

• Ketone Body-Mediated Ferroptosis Inhibition in Stroke Neurop

  2026-07-02

  This study reveals that remote ischemic postconditioning (RIPostC) confers neuroprotection after stroke by enhancing ketone body production, which suppresses ferroptosis in neurons. The findings highlight a mechanistic link between energy metabolism, iron homeostasis, and neuronal survival, offering new directions for therapeutic intervention.

• Letrozole: Protocol Optimization with a Non-Steroidal Aromat

  2026-07-02

  Letrozole from APExBIO empowers researchers to achieve precise and reproducible aromatase inhibition in breast cancer and neuroendocrine studies. This guide details robust experimental workflows, actionable troubleshooting strategies, and data-driven protocol enhancements, ensuring reliable estrogen biosynthesis modulation for advanced bench research.

• Vincristine Sulfate in Cancer Research: Applied Workflows &

  2026-07-01

  Vincristine sulfate’s role as a microtubule disrupter underpins its widespread adoption in cancer research models, from leukemia to solid tumor xenografts. This article delivers actionable protocols, troubleshooting guidance, and cross-study insights that empower researchers to maximize reproducibility and antitumor impact with APExBIO’s high-purity compound.

• Optimizing hiPSC-Derived Platelet Production via Small Molec

  2026-07-01

  This study presents an optimized, cost-effective protocol for generating functional platelets from human induced pluripotent stem cells (hiPSCs), overcoming previous barriers of low yield and high cost. The method leverages fine-tuned embryoid body input, serum-free media, and targeted small molecule modulation to enhance megakaryocyte differentiation and platelet function, with significant implications for regenerative medicine and cell therapy.

• Bafilomycin C1: Precision V-ATPase Inhibitor in Autophagy As

  2026-06-30

  Bafilomycin C1 enables precise dissection of lysosomal acidification and autophagy, supporting high-content screening and disease modeling in iPSC-derived systems. This article offers actionable workflows, troubleshooting, and expert-driven protocol optimization for robust, reproducible results in cancer biology and cardiotoxicity profiling.

• 6-Thioguanine Inhibits EV71 via BIRC3-Mediated Autophagy Sup

  2026-06-30

  This study uncovers that 6-thioguanine (6-TG) robustly inhibits enterovirus 71 (EV71) replication by downregulating BIRC3-mediated autophagy in vitro. The findings introduce a mechanistically novel antiviral strategy and provide a foundation for future therapeutic development against EV71-associated hand, foot, and mouth disease.

• RNF166 Destabilizes Angiomotins to Drive Colorectal Cancer P

  2026-06-29

  The referenced study reveals that the E3 ubiquitin ligase RNF166 accelerates colorectal cancer progression by specifically recognizing and destabilizing poly-ADP-ribosylated angiomotins, leading to YAP activation. These findings clarify a previously unknown regulatory mechanism within the Hippo pathway and suggest new therapeutic targets for colorectal cancer intervention.

• Mutational Drivers and Drug Resistance Pathways in Myeloma C

  2026-06-29

  This study provides the first comprehensive exome-wide map of mutations in human multiple myeloma cell lines, revealing both known and novel genetic alterations linked to tumor progression and drug resistance. The findings inform model selection for experimental research and illuminate potential therapeutic targets for hematological malignancies.

• Flavopiridol (L868275): Potent Pan-CDK Inhibitor for Cancer

  2026-06-28

  Flavopiridol, also known as L868275, is a highly selective pan-cyclin-dependent kinase inhibitor with nanomolar potency against CDK1, CDK2, CDK4, and CDK6. It is widely used as a cell cycle arrest agent in cancer research, demonstrating robust in vitro and in vivo efficacy. This dossier summarizes its validated mechanisms, key benchmarks, and workflow parameters for experimental reproducibility.

• Mitoxantrone in the Lab: Overcoming ABCG2 Barriers in Antica

  2026-06-27

  Explore advanced strategies for using Mitoxantrone in anticancer research, focusing on overcoming ABCG2-mediated drug resistance. This in-depth article offers unique practical insights and protocol recommendations for optimizing experimental outcomes.

• ELP4 and ZEB2 Regulate TCF7L2-Mediated Microglia Polarizatio

  2026-06-26

  This study delineates the antagonistic regulatory roles of ELP4 and ZEB2 on TCF7L2-driven microglia M1 polarization during ischemic stroke. The findings provide mechanistic insight into how modulation of TCF7L2 impacts neuroinflammation, highlighting possible molecular targets for intervention.

• Gallein: G Protein βγ Subunit Inhibitor for Translational As

  2026-06-26

  Gallein offers translational researchers a unique tool to dissect and modulate GPCR signaling in cancer, immunology, and metabolic disease models. Its validated use in macrophage polarization, cancer metastasis inhibition, and cardiometabolic disease research delivers robust, reproducible workflows and practical troubleshooting insights.

• Copper-Baicalein Nanoassemblies Induce Cuproptosis in Cancer

  2026-06-25

  This study introduces a baicalein–copper nanoassembly (BCB) that integrates chemodynamic and photodynamic mechanisms to induce cuproptosis—a copper-dependent cell death—specifically in bone-metastatic tumors. The work demonstrates improved tumor targeting, robust ROS generation, and high cure rates in preclinical models, suggesting a promising multimodal approach for difficult-to-treat cancers.

15879 records 1/1059 page Next 12345 下5页 Last page